Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wade Sexton

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Surgery|September 10, 2002
Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national databaseJudd W Moul, Hongyu Wu, Leon Sun, et al.
The Journal of Urology|February 10, 2004
Watchful waiting and factors predictive of secondary treatment of localized prostate cancerHongyan Wu, Leon Sun, Judd W Moul, et al.
Urologic Oncology|November 8, 2015
Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbiditiesScott M Haake, Samira A Brooks, Eric Welsh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen eraCorey A Carter, Timothy Donahue, Leon Sun, et al.
European Urology Oncology|July 16, 2025
Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder CancerChristopher Guske, Seyed Behzad Jazayeri, Christian Harrs, et al.
Clinical Genitourinary Cancer|January 3, 2022
Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed OpportunityJuskaran Chadha, Jacob J Adashek, Heather Jim, et al.
Urologic Oncology|August 24, 2021
Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladderNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
JAMA Network Open|May 25, 2021
Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell CarcinomaNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
The Journal of Urology|May 25, 2021
Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder CancerNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
The Journal of Urology|January 19, 2023
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial CarcinomaCraig Labbate, Solomon Woldu, Katie Murray, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Surgery|September 10, 2002
Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national databaseJudd W Moul, Hongyu Wu, Leon Sun, et al.
The Journal of Urology|February 10, 2004
Watchful waiting and factors predictive of secondary treatment of localized prostate cancerHongyan Wu, Leon Sun, Judd W Moul, et al.
Urologic Oncology|November 8, 2015
Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbiditiesScott M Haake, Samira A Brooks, Eric Welsh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen eraCorey A Carter, Timothy Donahue, Leon Sun, et al.
European Urology Oncology|July 16, 2025
Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder CancerChristopher Guske, Seyed Behzad Jazayeri, Christian Harrs, et al.
Clinical Genitourinary Cancer|January 3, 2022
Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed OpportunityJuskaran Chadha, Jacob J Adashek, Heather Jim, et al.
Urologic Oncology|August 24, 2021
Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladderNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
JAMA Network Open|May 25, 2021
Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell CarcinomaNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
The Journal of Urology|May 25, 2021
Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder CancerNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
The Journal of Urology|January 19, 2023
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial CarcinomaCraig Labbate, Solomon Woldu, Katie Murray, et al.
Pageof 3